Hengrui and Kailera Advance Oral Ribupatide Obesity Pill on Positive Phase 2 Data Showing Up to 12% Weight Loss

on

Hengrui Pharma and Kailera Therapeutics announced positive topline results from a Phase 2 trial of once-daily oral ribupatide (HRS9531/KAI-9531-T), a GLP-1/GIP dual agonist, in 166 adults with obesity in China.13

Participants achieved mean weight loss of up to 12.1% at 26 weeks (efficacy estimand I) or 11.9% at 50 mg dose (treatment policy estimand II), compared to 2% for placebo, with no plateau observed.123

Over 50% on the highest dose lost ≥10% body weight; gastrointestinal side effects were mild to moderate, with vomiting in ≤11.4% and nausea in ≤22.7%.134

Hengrui plans to rapidly advance to Phase 3 trial in China; Kailera to initiate global Phase 2 trial in 2026.135

This oral version complements injectable ribupatide, in global Phase 3 (KaiNETIC), which showed 23.6% weight loss at 36 weeks.3

News released February 10, 2026.24

Sources:

1. https://www.biopharmadive.com/news/kailera-hengrui-oral-ribupatide-study-results-china/811718/

2. https://www.fiercebiotech.com/biotech/kailera-hengrui-tout-promising-mid-stage-results-obesity-pill

3. https://www.kailera.com/press-release/kailera-therapeutics-and-hengrui-pharma-report-positive-topline-data-from-phase-2-obesity-trial-of-oral-ribupatide/

4. https://www.globenewswire.com/news-release/2026/02/10/3235172/0/en/Kailera-Therapeutics-and-Hengrui-Pharma-Report-Positive-Topline-Data-from-Phase-2-Obesity-Trial-of-Oral-Ribupatide.html

5. https://www.biospace.com/drug-development/kailera-hengrui-push-oral-glp-1-gip-pill-to-phase-3-after-clearing-mid-stage-china-study